Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
IPO Year: 2020
Exchange: NASDAQ
Website: immunome.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/8/2024 | $30.00 | Overweight | Stephens |
| 5/31/2024 | $27.00 | Overweight | Piper Sandler |
| 4/30/2024 | $24.00 | Overweight | JP Morgan |
| 4/15/2024 | $35.00 | Buy | Guggenheim |
| 1/29/2024 | $30.00 | Outperform | Leerink Partners |
| 12/19/2023 | $12.00 | Outperform | Wedbush |
| 10/29/2021 | $35.00 | Overweight | Cantor Fitzgerald |
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
10-Q - Immunome Inc. (0001472012) (Filer)
8-K - Immunome Inc. (0001472012) (Filer)
8-K - Immunome Inc. (0001472012) (Filer)
S-3ASR - Immunome Inc. (0001472012) (Filer)
8-K - Immunome Inc. (0001472012) (Filer)
10-Q - Immunome Inc. (0001472012) (Filer)
8-K - Immunome Inc. (0001472012) (Filer)
8-K - Immunome Inc. (0001472012) (Filer)
424B5 - Immunome Inc. (0001472012) (Filer)
10-Q - Immunome Inc. (0001472012) (Filer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
4 - Immunome Inc. (0001472012) (Issuer)
SC 13G/A - Immunome Inc. (0001472012) (Subject)
SC 13G - Immunome Inc. (0001472012) (Subject)
SC 13G - Immunome Inc. (0001472012) (Subject)
SC 13G/A - Immunome Inc. (0001472012) (Subject)
SC 13G/A - Immunome Inc. (0001472012) (Subject)
SC 13G/A - Immunome Inc. (0001472012) (Subject)
SC 13D/A - Immunome Inc. (0001472012) (Subject)
SC 13G/A - Immunome Inc. (0001472012) (Subject)
SC 13G - Immunome Inc. (0001472012) (Subject)
SC 13G - Immunome Inc. (0001472012) (Subject)
Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments. "2023 was a transformative year for Immunome as we closed the merger with Morphimmune, advanced our pipeline and expanded the company's leadership team," said Clay B. Siegall, Ph.D., President and Chief Executive Officer. "Th
- Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors - - Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO - - Bob Lechleider, M.D., appointed as Chief Medical Officer – - Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors - - Cash runway expected to extend into Q1 2026* - Immunome, Inc. (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the fourth quarter ended December 31, 2022 and provided a corporate update. "Looking back on the past year, the transformative strategic collaboration with AbbVie highlighted the disruptive nature of our discovery platform in finding novel antibody-target pairs based on human memory B-cell response," stated Purnanand Sarma, Ph.D., President and CEO of Immunome. "We look forward to continuing to execute on our momentum throughout the upcoming year as we advance our p
Immunome, Inc. (NASDAQ:IMNM), a clinical stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. "We look forward to completing our clinical trial for IMM-BCP-01, our COVID-19 antibody program, while continuing to expand our oncology portfolio including our planned submission of the IND for IMM-ONC-01 by mid-2023. Our Discovery Engine provides unique insights into how the human immune system sees disease and continues to highlight interesting areas of cancer biology and identify novel targets an
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced financial results for the third quarter ended September 30, 2024, and provided a business update. "Immunome continues to advance its pipeline," said Clay B. Siegall, Ph.D., President and Chief Executive Officer. "Topline data for the RINGSIDE Part B trial of AL102 is expected in the second half of 2025, and IND submissions for IM-1021 and IM-3050 are on track." "Our discovery team is focused on discovering ADCs that effectively pursue the novel targets we believe will define the next generation of transformative cancer therapie
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Wednesday, November 13th at 10:30am Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days. About Immunome, Inc. Immunome is a clinical-stage targeted oncology company
Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 31, 2024, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase 378,800 shares of common stock to 14 new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price equal to $11.47 per share, the Compa
IM-1021 showed superior potency when compared to a competitor in both mantle cell lymphoma and triple-negative breast cancer preclinical models; IND submission expected in 1Q25 HC74, Immunome's proprietary TOP1 ADC payload, shows superior potency, desirable ADME properties, and enhanced efficacy in chemo-resistant cell lines when compared to deruxtecan Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented promising preclinical data for IM-1021 and the associated proprietary ADC payload HC74. The results were presented in a poster entitled "Preclinical evaluation of IM-1021, a ROR1-targe
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster highlighting preclinical evaluation of IM-1021, a ROR1-targeted antibody drug conjugate (ADC), at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on October 24, 2024. Immunome expects to submit an IND for the IM-1021 program to the FDA in the first quarter of 2025. Following the presentation, a copy of the poster will be made available in the "Events & Presentations" portion of Immunome's website. Poster Presentation Details: Title: Preclinical evaluation of IM-102
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer (following the acquisition of Seagen in December 2023) and Eli Lilly & Company. "Roee further strengthens an Immunome team whose members have designed, developed and commercialized innovative targeted therapies for cancer patients," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.
Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 3, 2024, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 851,400 shares of common stock to 25 new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $13.43 per share, t
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster with updated results from the RINGSIDE Phase 2 clinical trial of AL102 for the treatment of desmoid tumors at the European Society of Medical Oncology (ESMO) Congress, being held in Barcelona from 13-17 September 2024. Enrollment in the Phase 3 portion of RINGSIDE was completed in February 2024, and Immunome expects to report topline data from that trial in the second half of 2025. Following the presentation, a copy of the poster will be made available in the "Events & Presentations" portion of Immunome's webs
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 5:35 P.M. Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days. About Immunome, Inc. Immunome is a clinical-stage targeted onco
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced financial results for the second quarter ended June 30, 2024, and provided a business update. "Immunome is focused on establishing and developing a broad pipeline of differentiated oncology therapies. We continue to advance work required to prepare AL102 for regulatory submissions, and we are moving towards submitting INDs for IM-1021 and IM-3050," said Clay B. Siegall, Ph.D., President and Chief Executive Officer. "These programs are supported by an expanding team of drug developers, including leaders who previously contributed
Stephens initiated coverage of Immunome with a rating of Overweight and set a new price target of $30.00
Piper Sandler initiated coverage of Immunome with a rating of Overweight and set a new price target of $27.00
JP Morgan initiated coverage of Immunome with a rating of Overweight and set a new price target of $24.00
Guggenheim initiated coverage of Immunome with a rating of Buy and set a new price target of $35.00
Leerink Partners initiated coverage of Immunome with a rating of Outperform and set a new price target of $30.00
Wedbush initiated coverage of Immunome with a rating of Outperform and set a new price target of $12.00
Cantor Fitzgerald initiated coverage of Immunome with a rating of Overweight and set a new price target of $35.00
Under the terms of the agreement, Nectin granted Immunome an exclusive, worldwide, all-fields license to monoclonal antibodies that are directed to a single undisclosed target. Immunome will be responsible for the research, development, manufacturing and commercialization of products incorporating these antibodies. Nectin will receive an upfront payment and will be eligible for milestones and royalties.
In the preceding three months, 4 analysts have released ratings for Immunome (NASDAQ:IMNM), presenting a wide array of perspectives from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 2 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.75, a high estimate of $35.00, and a low estimate of $24.00. This current average reflects an in
Piper Sandler analyst Biren Amin initiates coverage on Immunome (NASDAQ:IMNM) with a Overweight rating and announces Price Target of $27.
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. ProFrac Holding The Trade: ProFrac Holding Corp. (NASDAQ:ACDC) 10% owner Dan H. Wilks acquired a total of 1,013,930 shares
Gainers Rezolute (NASDAQ:RZLT) stock increased by 52.7% to $4.58 during Tuesday's after-market session. The company's market cap stands at $183.8 million. The company's, Q3 earnings came out 4 days ago. Mustang Bio (NASDAQ:MBIO) stock increased by 30.64% to $0.41. The company's market cap stands at $5.0 million. The company's, Q1 earnings came out 4 days ago. Qilian Intl Hldg Gr (NASDAQ:QLI) shares rose 14.77% to $0.87. The company's market cap stands at $31.1 million. MyMD Pharmaceuticals (NASDAQ:MYMD) shares increased by 12.68% to $2.31. The market value of their outstanding shares is at $4.9 million. The company's, Q4 earnings came out 4 days ago. Immunome (NASDAQ:IMNM) shares moved
- SEC Filing
Rosett most recently held the role of Executive Vice President, Operations, in addition to serving as Immunome's Interim Chief Financial Officer since January 2024.
Immunome (NASDAQ:IMNM) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $(0.69) by 263.77 percent. This is a 617.14 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $1.03 million which missed the analyst consensus estimate of $2.50 million by 58.84 percent. This is a 56.47 percent decrease over sales of $2.36 million the same period last year.
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer (following the acquisition of Seagen in December 2023) and Eli Lilly & Company. "Roee further strengthens an Immunome team whose members have designed, developed and commercialized innovative targeted therapies for cancer patients," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.
Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders, such as autism spectrum disorder, announced today the appointment of Dr. Purnanand Sarma, PhD, as Chair of its Board of Directors. Dr. Sarma, who will hold the title of Executive Chairman, will actively support the strategic development of STALICLA, working closely with the CEO, Lynn Durham, and the management team. With an
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Tsai, PhD, as Chief Technical Officer. Dr. Tsai has nearly three decades of experience in product development, process optimization, and manufacturing, particularly in the area of antibody-drug conjugates (ADCs). "Immunome is excited to add Phil to our management team as we advance our pipeline of differentiated targeted cancer therapies," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome. "With the Phase 3 trial of AL102 for the treatment of desmoid tumors fully enrolled, two IND filings p
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Kinney Horn as Chief Business Officer. Mr. Horn brings to Immunome extensive experience across life sciences corporate and business development, alliance management, and commercial strategy. "Immunome is excited to welcome Kinney to our executive team as we advance our broad pipeline of targeted therapies," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome. "With the recent acquisition of AL102, Immunome is now a clinical stage company, and Kinney's expertise in navigating the complex business l
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors. Dr. Swain has over 30 years of oncology clinical research experience and has served on both public company and non-profit boards. "Immunome is pleased to welcome Sandra to the Board of Directors, especially given her extensive experience as a successful clinical researcher," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome. "Her deep understanding of oncology and patient care will add a valuable perspective as we advance AL102 through Phase 3 an
AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors, effective March 1, 2024. Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck. "It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors," said Taylor Schre
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Roberts as Chief Technical Officer. Mr. Roberts has over three decades of experience in product development, global manufacturing, and commercialization of novel pharmaceutical products. "Immunome is delighted to add Phil to our management team as we advance our portfolio of immunotherapies, radioligand therapies, and ADCs towards clinical development," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome. "With an ambitious pipeline that spans multiple modalities, Phil's technical leadership
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Carol A. Schafer to its Board of Directors. Ms. Schafer has more than 25 years of experience in investment banking and equity capital markets and has served as a corporate director for multiple public companies. "Carol's financial expertise, strategic insight and understanding of equity markets will greatly benefit Immunome as we continue to expand and advance our pipeline of targeted oncology therapeutics," stated Clay B. Siegall, Ph.D., Chairman and Chief Executive Officer of Immunome. "The Immunome leadership team wil
- Accomplished biotechnology and pharmaceutical executive with over three decades of experience to join Immunome's Board of Directors - Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Jean-Jacques "JJ" Bienaimé to its Board of Directors. Mr. Bienaimé has over three decades of experience in the biotechnology and pharmaceutical industries, most recently serving as Chairman and Chief Executive Officer of BioMarin Pharmaceuticals. "Immunome is pleased to welcome JJ to the Board of Directors as we enter our next stage of growth," stated Clay Siegall, PhD, President and C
- Seasoned biotechnology executive and board-certified physician in medical oncology joins executive team as Immunome advances growing pipeline of cancer therapies - Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer. Dr. Lechleider brings over 20 years of experience as an academic and industry executive in medical oncology and cancer research. "We are delighted to welcome Bob to our team during an exciting time in Immunome's growth as we focus on advancing our oncology pipeline into the clinic," said Dr. Siegall, Presiden